This review will discuss the mechanisms of BTK inhibition, review AEs associated with ibrutinib therapy, together with their possible underlying molecular basis, and AEs reported with acalabrutinib therapy in patients with CLL, including recommendations for the management of acalabrutinib-related AEs. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.